For the use of a Registered Medical Practitioner or a Hospital or a Laboratory

INACTIVATED INFLUENZA VACCINE (SPLIT VIRION) I.P

VAXIGRIP®

Suspension for Injection in multidose vial

NH-2021-2022 strains

1. NAME OF THE MEDICINAL PRODUCT

VAXIGRIP, suspension for injection in multidose vial.

Influenza vaccine (split virion, inactivated).

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Influenza virus (inactivated, split) of the following strains*:
Each 0.5 ml dose contains:

- A/Victoria/2570/2019 (H1N1)pdm09 - like strain (A/Victoria/2570/2019, IVR-215)

.....15 micrograms HA**

- A/Cambodia/e0826360/2020 (H3N2) - like strain (A/Tasmania/503/2020, IVR-221) ……. 15 micrograms HA**
- B/Washington/02/2019 - like strain (B/Washington/02/2019, wild type) ----------15 micrograms HA**

* propagated in fertilised hens' eggs from healthy chicken flocks

** haemagglutinin

This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2021-2022 season.

Excipients:
Thiomersal..... 2 micrograms per 0.5 ml dose

For the full list of excipients, see Section 6.1.

VAXIGRIP may contain traces of eggs, such as ovalbumin, and of neomycin, formaldehyde and octoxinol-9, which are used during the manufacturing process (see Section 4.3).

3. PHARMACEUTICAL FORM

Suspension for injection in multidose vial.

The vaccine, after shaking gently, is a slightly whitish and opalescent liquid.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Prophylaxis of influenza.

VAXIGRIP is indicated in adults and children from 6 months of age.

The use of VAXIGRIP should be based on official recommendations.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory

4.2 Posology and method of administration

Posology

Adults: 0.5 ml.

Paediatric population

Children from 36 months onwards: 0.5 ml.

Children from 6 months to 35 months: 0.25 ml. Clinical data are limited.

For children less than 9 years who have not previously been vaccinated, a second dose should be given after an interval of at least 4 weeks.

Children less than 6 months: the safety and efficacy of VAXIGRIP in children less than 6 months have not been established. No data are available.

Method of administration

Immunisation should be carried out by intramuscular or deep subcutaneous injection.

For adults and children from 36 months of age: the preferred site for intramuscular injection is the deltoid muscle.

For children from 12 to 35 months of age: the preferred site for intramuscular injection is the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate).

For children from 6 to 11 months of age: the preferred site for intramuscular injection is the anterolateral aspect of the thigh.

Precautions to be taken before handling or administering the medicinal product

For instructions on preparation of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substances, to any of the excipients listed in Section 6.1, including thiomersal or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), neomycin, formaldehyde and octoxinol-9.

Vaccination should be postponed in case of moderate or severe febrile disease or acute disease.

4.4 Special warnings and precautions for use

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

VAXIGRIP should under no circumstances be administered intravascularly.

As with other vaccines administered intramuscularly, the vaccine should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions.

As with any vaccine, vaccination with VAXIGRIP may not protect 100% of susceptible individuals.

Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.

Interference with serological testing

See Section 4.5.

4.5 Interaction with other medicinal products and other forms of interaction

VAXIGRIP may be given at the same time as other vaccines. Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified.

The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.

Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the false-positive ELISA test results. The transient false positive reactions could be due to the IgM response by the vaccine.

4.6 Fertility, pregnancy and lactation

Pregnancy

Inactivated influenza vaccines can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of inactivated influenza vaccines do not indicate any adverse foetal and maternal outcomes attributable to the vaccine.

Breastfeeding

VAXIGRIP may be used during breastfeeding.

Fertility

No fertility data are available.

4.7 Effects on ability to drive and use machines

VAXIGRIP has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

a. Summary of the safety profile

In clinical trials approximately 10,300 individuals from 6 months of age received VAXIGRIP thiomersal-free formulation.

Depending on immunization history and the age of the children, the dosage and the number of doses were different (see *Paediatric population* in subsection b. Tabulated list of adverse reactions).

Most of adverse reactions usually occurred within the first 3 days following injection of VAXIGRIP, resolved spontaneously within 3 days after onset. The intensity of these reactions was mild to moderate intensity.

The most frequently reported injection site reaction within 7 days following injection of VAXIGRIP was injection site pain in all population.

The most frequently reported systemic reaction within 7 days following injection of VAXIGRIP was headache in adults, elderly and children from 9 to 17 years of age, myalgia in children from 3 to 8 years, fever in children from 24 to 35 months of age and irritability in children from 6 to 23 months of age.

b. Tabulated list of adverse reactions

The data below summarize the frequencies of the adverse reactions that were recorded following vaccination with VAXIGRIP during clinical trials and worldwide post-marketing experience.
Adverse events are ranked under headings of frequency using the following convention:
Very common (≥1/10);
Common (≥1/100 to <1/10);
Uncommon (≥1/1,000 to <1/100);
Rare (≥1/10,000 to <1/1,000);

Very rare (<1/10,000),
Not known (cannot be estimated from available data).

Adult and elderly
The safety profile is based on data:
- from clinical trials in more than 5,000 adults and 4,400 elderly over 60 years of age,
- from worldwide post-marketing experience in the overall population (*).

ADVERSE REACTIONS	FREQUENCY
Blood and Lymphatic System Disorders	
Lymphadenopathy [1]	Uncommon
Transient thrombocytopenia	Not known*
Immune System Disorders	
Allergic reactions such as drug hypersensitivity [2], dermatitis atopic [2], urticaria [2, 5], oropharyngeal pain, asthma [1], rhinitis allergic [2], rhinorrhea [1], conjunctivis allergic [2]	Uncommon
Allergic reactions such as swelling face, pruritus [2, 5], erythema, rash, flushing [3], oral mucosal eruption [3], paraesthesia oral [3], throat irritation, dyspnea [2, 5], sneezing, nasal obstruction [2], upper respiratory tract congestion [2], ocular hyperaemia [2]	Rare
Allergic reactions such as, rash erythematous, angioedema, shock	Not known*
Nervous System Disorders	
Headache	Very common
Dizziness [7], somnolence [7]	Uncommon
Hypoaesthesia [2], paresthesia	Rare
Neuralgia, convulsions, encephalomyelitis, neuritis, Guillain Barré Syndrome	Not known*
Vascular disorders	
Vasculitis such as Henoch-Schonlein purpura, with transient renal involvement in certain cases	Not known*
Gastrointestinal Disorders	
Diarrhea, nausea	Uncommon
Abdominal pain [2], vomiting	Rare
Skin and Subcutaneous System Disorders	
Hyperhidrosis [1]	Uncommon
Metabolism and Nutrition Disorders	
Decreased appetite	Rare
Musculoskeletal and Connective Tissue Disorders	
Myalgia	Very common
Arthralgia [1]	Uncommon
General Disorders and Administration Site Conditions	
Injection site pain, malaise [4]	Very common

Fever [6], shivering, injection site erythema, injection site induration, injection site swelling/oedema	Common
Asthenia [1], fatigue, injection site ecchymosis, injection site pruritus, injection site warmth [1], injection site discomfort	Uncommon
Flu-like symtoms [2], injection site exfoliation [3], injection site hypersensitivity [2]	Rare

[1] Rare in elderly
[2] Reported during clinical trials in adults
[3] Reported during clinical trials in elderly
[4] Common in elderly
[5] Not known in elderly
[6] Uncommon in elderly
[7] Rare in adults

Paediatric population

Depending on immunization history, children from 6 months to 8 years received one or two doses of VAXIGRIP. Children/adolescents from 9 to 17 years of age received one dose.
Children from 6 to 35 months of age received the 0.25 ml formulation, and children from 3 years of age received the 0.5 ml formulation.

- Children/adolescents from 3 to 17 years of age:

The safety profile is based on data:
- from clinical trials in 363 children from 3 to 8 years and in 296 children/adolescents from 9 to 17 years of age,
- from worldwide post-marketing experience in the overall population (*).

In children from 3 to 8 years of age, the most frequently reported reactions within 7 days following injection of VAXIGRIP were injection site pain (59.1%), injection site erythema/redness (30.3%), myalgia (25.0%), malaise (22.3%) and injection site swelling/oedema (22.1%).

In children/adolescents from 9 to 17 years of age, the most frequently reported reactions within 7 days following injection of VAXIGRIP were injection site pain (65.3%), headache (28.6%) and myalgia (27.6%).

ADVERSE REACTIONS	FREQUENCY
Blood and Lymphatic System Disorders	
Lymphadenopathy [1, 6]	Uncommon
Transient thrombocytopenia	Not known*
Immune System Disorders	
Allergic reactions such as urticaria, rash, pruritus [1, 6], oropharyngeal pain [1]	Uncommon
Allergic reactions such as rash erythematous, dyspnea, angioedema, shock	Not known*
Nervous System Disorders	
Headache	Very common
Dizziness [2]	Uncommon
Neuralgia, paresthesia, convulsions, encephalomyelitis, neuritis and Guillain Barré Syndrome	Not known*
Vascular disorders	
Vasculitis such as Henoch-Schonlein purpura, with transient renal involvement in certain cases	Not known*
Gastrointestinal Disorders	
Diarrhea [1], abdominal pain [1]	Uncommon
Musculoskeletal and Connective Tissue Disorders	

Myalgia	Very common
General Disorders and Administration Site Conditions	
Injection site pain, injection site erythema, injection site swelling/oedema, injection site induration [3], malaise, shivering [4]	Very common
Fever, injection site ecchymosis [5]	Common
Injection site pruritus, injection site warmth [2], injection site discomfort [2], crying [1], asthenia [2], fatigue	Uncommon

[1] Reported during clinical trials in children from 3 to 8 years old
[2] Reported during clinical trials in children/adolescents from 9 to 17 years old
[3] Common in children/adolescents from 9 to 17 years old
[4] Common in children from 3 to 8 years old
[5] Uncommon in children/adolescent from 9 to 17 years old
[6] Not known in children/adolescents from 9 to 17 years old

- Children from 6 to 35 months of age:

The safety profile is based on data:
- from clinical trials in 101 children from 6 to 35 months of age,
- from worldwide post-marketing experience in the overall population (*).

The most frequently reported reactions within 7 days following injection of VAXIGRIP were irritability (50.9%), injection site tenderness (36.6%), injection site erythema (34.0%), abnormal crying (34.0%), fever (29.0%) and appetite lost (28.3%).

ADVERSE REACTIONS	**FREQUENCY**
Blood and Lymphatic System Disorders	
Transient thrombocytopenia, lymphadenopathy	Not known*
Immune System Disorders	
Allergic reactions such as pruritus, rash erythematous, urticaria, dyspnea, angioedema, shock	Not known*
Metabolism and nutrition Disorders	
Appetite lost [1]	Very common
Psychiatric Disorders	
Crying abnormal [1], irritability [1]	Very common
Nervous System Disorders	
Headache [2], drowsiness [1]	Very common
Paresthesia, convulsions, encephalomyelitis	Not known*
Vascular disorders	
Vasculitis such as Henoch-Schonlein purpura, with transient renal involvement in certain cases	Not known*
Gastrointestinal Disorders	
Diarrhea, vomiting [1]	Common
Musculoskeletal and Connective Tissue Disorders	
Myalgia [2]	Very common

General Disorders and Administration Site Conditions	
Injection site tenderness, injection site erythema, , injection site induration, injection site ecchymosis, injection site swelling/oedema, fever	Very common
Shivering [(2)]	Common

[(1)] Reported in children from 6 to 23 months old
[(2)] Reported in children from 24 to 35 months old

c. Description of selected adverse reactions

This vaccine contains thiomersal (an organomercuric compound) as a preservative and therefore, hypersensitivity reactions may occur (see Section 4.3).

d. Other special populations

Although only a limited number of subjects with co-morbidities were enrolled, studies conducted in renal transplant patients, asthmatic patients, or children from 6 months to 3 years of age with medical conditions being at especially high risk of developing serious flu-related complications showed no major differences in terms of safety profile of VAXIGRIP in these populations.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed.

4.9 Overdose

Cases of administration of more than the recommended dose (overdose) have been reported with VAXIGRIP. When adverse reactions were reported, the information was consistent with the known safety profile of VAXIGRIP described in Section 4.8.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB02

An antibody immune response is generally induced within 2 to 3 weeks. The duration of postvaccinal induced immunity varies but is usually 6-12 months.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Not applicable.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Thiomersal 2mcg/0.5 ml and Buffer solution q.s 0.5 mL:
- Sodium chloride 8g/L

- Potassium chloride 0.2g/L
- Disodium phosphate dihydrate 1.15g/L
- Potassium dihydrogen phosphate : 0.2 g/L
- Water for injections….q.s

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

1 year.
Shelf life after opening: 7 days

Do not use VAXIGRIP after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light.

6.5 Nature and contents of container

5 ml of suspension in vial (type I glass) with a stopper (chlorobutyl) – box of 1 or 10 vials of 10 doses.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

The vaccine should be allowed to reach room temperature before use.

Shake before use. Inspect visually prior to administration.

After removal of the first dose, the vaccine contained in the vial must imperatively be used within 7 days.

For each dose taken and for each patient, a new sterile syringe fitted with a new sterile needle is used.

Between different removals and in any case within 5 minutes maximum after removal of the last dose, the vial should be placed back in the refrigerator to keep the product at the required temperature, i.e. between 2°C and 8°C (never in the freezer).

A partially used vial must be destroyed immediately if:

- Sterile removal has not been strictly carried out,
- There is any suspicion that a partially used vial has been contaminated,
- There is visible sign of contamination, such as a change in the appearance or the presence of particles in suspension.

In any case, when in storage period, the vial should be stored according to the conditions described in the manufacturer’s instructions for use.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory

7. Manufactured by:

Sanofi Pasteur

Parc Industriel d'Incarville

27100 Val de Reuil- France.

8. Imported and marketed by:

Sanofi Healthcare India Private Limited, Gala No. 4, Ground Floor, Building No. B1, Citylink Warehousing Complex,S No.121/10/A,121/10/B & 69, NH3, VADAPE, Tal: BHIWANDI-16, (THANE-Z5),PIN 421302

For further information please contact:

Sanofi Healthcare India Private Limited,

Sanofi House, C.T.S No.-117-B, L & T Business Park,

Saki Vihar Road, Powai, Mumbai 400 072-India.

Registered medical practitioners can refer to the company website www.sanofi.in for the latest prescribing information.

Updated : Dec 2021 (WHO recommendations for NH-2021-2022 season).

Version -7.0, based on CCDS version 9 dated 26 October 2017